Feb 27, 2007|
Pharma: Where is it headed?
The period December 2006-February 2007 has not seen a strong performance by the pharma stocks under our coverage with only 3 stocks (out of 12) managing to beat the Sensex. Having said that, the Sensex declined by 1.5% during the said period. In this article, we shall take a look at the 4 stocks in the pharma sector that have managed to perform better than the BSE Healthcare index during the above mentioned period.
Pharma: The top gainers from Dec 2006 to Feb 2007
Biocon: Biocon was the best performer of the lot notching an impressive 22% gain, leaving its competition far behind. The surge in the stock can be attributed to the robust set of numbers announced by the company for 3QFY07. After a slew of poor quarters, the company bounced back during 3QFY07 mainly led by the 'Pravastatin' and 'Simvastatin' supplies to the US market and a robust growth in its contract research businesses. With the manufacturing facilities in Biocon Park turning operational, this has translated into cost savings for the company resulting in operating margin expansion and growth in profitability. However, the dependence on statins is an area of concern going forward and the contribution from the other biopharmaceutical products to total revenues will be the critical driver in the future.
Glenmark: Glenmark was the second best performer in the three-month period having recorded gains of 2.4%. The company signed an agreement with Merck for out-licensing the former's anti-diabetic molecule for milestone payments of around 190 m euros and received the first upfront payment of 25 m euros in 3QFY07. Besides this, the company also reported strong numbers for the December 2006 quarter largely driven by strong performances by both the US and Latin American markets. Going forward, while the ramp up in the US and Latin American operations are expected to contribute to the overall performance, any adverse developments on the R&D front could impact the receipt of the milestone payments for the 2 out-licensed drugs.
GSK Pharma: GSK Pharma recorded a marginal gain of 0.3% but beat both the Sensex and the BSE Healthcare index during the three-month period. While the full year performance of the company was impacted by supply shortages and the sale of its animal healthcare business, the company reported an improvement in operating margins and at present has the best operating margins among its peers in the MNC pharma space. Going forward, GSK Pharma plans to launch 3 new products in the domestic market in CY07 and the company intends to keep its product portfolio fresh by launching products from its parent's folio and also through the in-licensing route. The company also plans to increase its focus on the chronic therapy segment, which is growing at a faster pace than the acute therapy segment.
Nicholas Piramal: Though Nicholas Piramal lost ground from December 2006 to February 2007 declining by 1.6%, the fall was much lesser than the Healthcare index and that of most of its domestic peers. The increasing contribution from its custom manufacturing business (with global innovator companies) to total revenue has led the company to report strong results for 3QFY07. Nicholas' strategy involves partnering with global pharma majors to drive its custom pharma sales rather than focus on generics and this is expected to be the key growth driver going forward. The company has been active on the acquisition front too acquiring Avecia and Pfizer's Morpeth facility in the UK to further bolster its custom manufacturing revenues.
To sum up...
From a long-term perspective, the outlook for the sector is positive with growth in generics expected to play a key role to drive revenues of domestic pharma companies. With pressures on global pharma innovators to reduce costs and spruce up margins, the CRAMS model is also expected to benefit in a big way. For MNC pharma companies, which are heavily focused on the domestic market, introduction of new products will be critical. Concerns remain with the increased competition and pricing pressures in the global generics market. For MNC pharma, 'price negotiation' for patented products will be the key factor to watch out for. More importantly, the announcement of new DPCO policy will play a crucial role in determining the fortunes of the Indian pharma companies (both domestic and MNCs). Having said that, considering all these factors, valuations of companies are important and investors need to adopt a stock-specific strategy while investing in the sector.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407